RESUMEN
Erythroderma, an inflammatory skin condition characterized by widespread erythema with variable degrees of exfoliation, pustulation, or vesiculobullous formation, is associated with high morbidity and mortality. Determining the underlying cause of erythroderma frequently presents a diagnostic challenge, which may contribute to the condition's relatively poor prognosis. This review covers the clinical presentation, pathophysiology, diagnosis, and treatment of erythroderma. It discusses similarities and differences among the many underlying etiologies of the condition and differences between erythrodermic and non-erythrodermic presentations of the same dermatosis. Finally, this article explores current research that may provide future tools in the diagnosis and management of erythroderma.
Asunto(s)
Dermatitis Exfoliativa , Humanos , Dermatitis Exfoliativa/diagnóstico , Dermatitis Exfoliativa/etiología , Dermatitis Exfoliativa/terapia , Adulto , Diagnóstico Diferencial , Piel/patología , PronósticoRESUMEN
Erythroderma is characterized by diffuse erythema and scale covering over 90% body surface area that can affect individuals with inflammatory dermatoses such as psoriasis. Complications of erythrodermic psoriasis include infection and cardiovascular compromise. Here we present a case of a 68 year-old man who was hospitalized for erythrodermic psoriasis refractory to multiple immunosuppressive and immunomodulatory therapies, ultimately developing sepsis due to bacteremia and fungemia complicated by infective endocarditis and a mycotic aneurysm. Although the widespread loss of epidermal function in erythroderma increases the risk of infection by opportunistic pathogens, water loss, and electrolyte imbalances, there are very few reported cases of psoriatic erythroderma complicated by fungemia and mycotic aneurysm. Given the high mortality associated with widespread epidermal dysfunction, there is a great need for evidence-based treatment guidelines for psoriatic erythroderma. J Drugs Dermatol. 2024;23(8): doi:10.36849/JDD.7751.
Asunto(s)
Aneurisma Infectado , Dermatitis Exfoliativa , Psoriasis , Choque Séptico , Humanos , Masculino , Psoriasis/complicaciones , Psoriasis/tratamiento farmacológico , Psoriasis/diagnóstico , Anciano , Dermatitis Exfoliativa/diagnóstico , Dermatitis Exfoliativa/etiología , Dermatitis Exfoliativa/terapia , Dermatitis Exfoliativa/tratamiento farmacológico , Choque Séptico/diagnóstico , Choque Séptico/microbiología , Choque Séptico/terapia , Choque Séptico/etiología , Aneurisma Infectado/diagnóstico , Aneurisma Infectado/terapia , Aneurisma Infectado/microbiología , Resultado Fatal , Fungemia/diagnóstico , Fungemia/tratamiento farmacológico , Fungemia/microbiología , Fungemia/complicaciones , Guías de Práctica Clínica como Asunto , Bacteriemia/diagnóstico , Bacteriemia/tratamiento farmacológico , Bacteriemia/complicaciones , Bacteriemia/microbiologíaRESUMEN
Diagnosing and treating neonatal and infantile erythroderma can be challenging due to the wide variety of potential causes. Neonatal erythroderma is rare and is associated with a high mortality rate due to complications of erythroderma itself and potential life-threatening underlying diseases. Prolonged erythroderma should always be a warning sign and an indication for referral to a hospital where a multidisciplinary team approach is possible. The role of a pediatric dermatologist is to keep in mind the wide spectrum of differential diagnoses that could be causing the condition and the determination of the final diagnosis. To avert a delay in establishing the correct diagnosis, we suggest adhering to specific guidelines. We reviewed available guidelines and adapted a step-by-step approach for use in Slovenia. We also discuss a case of a neonate with erythroderma to illustrate the applicability of the proposed guidelines. Our patient presented with persistent erythroderma, pustules on the trunk and limbs, and intertriginous dermatitis. Despite local corticosteroid treatment, the skin redness persisted. After the exclusion of a systemic infection and additional tests, Omenn syndrome was diagnosed as the underlying cause.
Asunto(s)
Dermatitis Exfoliativa , Inmunodeficiencia Combinada Grave , Recién Nacido , Humanos , Niño , Dermatitis Exfoliativa/diagnóstico , Dermatitis Exfoliativa/terapia , Dermatitis Exfoliativa/etiología , Inmunodeficiencia Combinada Grave/complicaciones , Inmunodeficiencia Combinada Grave/diagnóstico , Inmunodeficiencia Combinada Grave/terapia , Diagnóstico Diferencial , EsloveniaRESUMEN
Erythroderma is an uncommon but serious dermatologic disorder that often requires hospitalization for diagnosis and treatment. However, little is known about predictors influencing cost and patient outcomes. The present study sought to characterize the sociodemographic factors that predict patient outcomes and hospital cost. Data were obtained from the 2016-2018 National Inpatient Sample (NIS) provided by the Healthcare Cost and Utilization Project from the Agency for Healthcare Research and Quality for patients of any age with a primary or secondary diagnosis of exfoliative dermatitis. Regression analyses were performed to find predictors for hospital costs and patient outcomes, represented by the length of stay (LOS). Univariate analysis of LOS revealed urban teaching hospitals were associated with prolonged LOS (p = 0.023). Univariate analysis of hospital cost yielded the following factors associated with increased hospital cost: Black and Asian patients (p = .045), urban teaching hospitals (p = .035), and northeast or south geographic location (p = .004). Multivariable regression analysis revealed prolonged LOS was associated with female sex (p = .043) and large bed capacity (p = .044) while shorter LOS was associated with increased age (p = .025); lower hospital costs were associated with private-owned hospitals - (p = .025). In patients diagnosed with erythroderma, there appear to be racial, economic, and geographic disparities for patients that lead to greater hospital costs and longer LOS.
Asunto(s)
Dermatitis Exfoliativa , Humanos , Femenino , Estados Unidos/epidemiología , Tiempo de Internación , Estudios Transversales , Dermatitis Exfoliativa/diagnóstico , Dermatitis Exfoliativa/epidemiología , Dermatitis Exfoliativa/terapia , Pacientes Internos , Factores SocioeconómicosRESUMEN
Erythrodermic psoriasis is a relatively rare, more dangerous inflammatory variant of psoriasis associated with high morbidity and mortality. It can be exceptionally challenging to manage, defeating even the most experienced dermatologist's arsenal of treatment strategies. Goeckerman therapy, a regimen of ultraviolet B phototherapy and crude coal tar, has demonstrable efficacy in severe and recalcitrant plaque-type psoriasis. However, its utility in erythrodermic psoriasis has not been explored within the dermatology literature. Herein, we present a patient with a long-standing history of erythrodermic psoriasis refractory to eleven treatment modalities including four biologic agents, who had his erythroderma 'turned around' following Goeckerman therapy. 'Turned around' is used to describe dramatically reducing a patient's cutaneous inflammation so that previously recalcitrant disease can now respond to maintenance therapy. The importance of a one to three week 'cool down' period of topical corticosteroid therapy prior to phototherapy or crude coal tar use is highlighted in this case as well. Although Goeckerman therapy is no longer regularly used, it remains one of the most efficacious treatments available for intractable psoriasis, attracting patients from all over the country desperate for symptom relief. This case suggests it may be useful in 'turning around' extremely difficult-to-treat erythrodermic psoriasis as well.
Asunto(s)
Alquitrán/uso terapéutico , Dermatitis Exfoliativa/terapia , Psoriasis/terapia , Terapia Ultravioleta , Terapia Combinada , Dermatitis Exfoliativa/complicaciones , Resistencia a Medicamentos , Femenino , Humanos , Masculino , Psoriasis/complicacionesRESUMEN
Erythroderma (exfoliative dermatitis), first described by Von Hebra in 1868, manifests as a cutaneous inflammatory state, with associated skin barrier and metabolic dysfunctions. The annual incidence of erythroderma is estimated to be 1-2 per 100 000 population in Europe with a male preponderance. Erythroderma may present at birth, or may develop acutely or insidiously (due to progression of an underlying primary pathology, including malignancy). Although there is a broad range of diseases that associate with erythroderma, the vast majority of cases result from pre-existing and chronic dermatoses. In the first part of this two-part concise review, we explore the underlying causes, clinical presentation, pathogenesis and investigation of erythroderma, and suggest potential treatment targets for erythroderma with unknown causes.
Asunto(s)
Dermatitis Exfoliativa/diagnóstico , Dermatitis Exfoliativa/etiología , Dermatitis Exfoliativa/epidemiología , Dermatitis Exfoliativa/terapia , Europa (Continente)/epidemiología , Femenino , Humanos , Incidencia , MasculinoRESUMEN
Leiner's disease (LD) is a rare and serious syndrome of infantile erythroderma of severe and progressive generalized seborrheic-like dermatitis, recalcitrant diarrhea, malabsorption and wasting, and recurrent local and systemic infections. The purpose of this study is to provide an updated review on management with a summarized review of available peer-reviewed articles on LD. The mechanisms underlying this disease process remain unclear. The diagnosis includes demonstration of deficient opsonic activity along with the clinical tetrad of erythroderma, persistent gastrointestinal disturbance, superimposed bacterial or candidal infection, and marked wasting. An important correlation between LD and defective yeast and Staphylococcus aureus opsonization has been established. For the familial form of LD, an association of either complement three deficiency or complement five dysfunction has been made. LD should be distinguished from other types of infantile erythroderma, including Omenn syndrome. Treatment includes fluid and nutrition replacement, antibiotics to control infection, and fresh-frozen plasma therapy. The prognosis is unclear; it depends on treatment. LD is a life-threatening condition that requires prompt identification and hospitalization. Affected infants who receive vigorous treatment not only have the prospect of surviving, but also generally lead a normal life after infancy.
Asunto(s)
Complemento C5/deficiencia , Dermatitis Exfoliativa , Enfermedades por Deficiencia de Complemento Hereditario , Antibacterianos/uso terapéutico , Dermatitis Exfoliativa/diagnóstico , Dermatitis Exfoliativa/etiología , Dermatitis Exfoliativa/terapia , Enfermedades por Deficiencia de Complemento Hereditario/diagnóstico , Enfermedades por Deficiencia de Complemento Hereditario/etiología , Enfermedades por Deficiencia de Complemento Hereditario/terapia , Humanos , LactanteRESUMEN
The present authors have previously reported that chronic idiopathic erythroderma (CIE) that lasts for more than 3 months without specific causes occurs almost exclusively in older men. No standardized therapeutic treatments for the condition have been established to date. To assess the efficacies and safeties of current treatments for CIE, the present authors reviewed cases of CIE. Twenty cases were identified, of which CIE was treated with oral corticosteroids, oral cyclosporine A (CsA), ultraviolet therapy, or a combination of these therapies. CIE was cured in 8/20 (40%) of these cases, and the average time to cure was 19.3 months. Oral CsA was the most effective treatment at relatively low doses (50-100 mg/day), which resulted in cures in four cases. Ultraviolet therapy also effectively cured two subjects, and oral corticosteroids cured one patient. In patients that were treated with oral CsA or corticosteroids, the terminations of the treatments within 2 to 3 months resulted in relapses in multiple patients. The maintaining of the treatments for a certain period may be necessary in cases that involve treatments with these orally administered drugs. Although CIE is a chronic and potentially refractory disease, it can evidently be cured or well controlled via appropriate long-term therapies.
Asunto(s)
Corticoesteroides/administración & dosificación , Ciclosporina/administración & dosificación , Dermatitis Exfoliativa/terapia , Terapia Ultravioleta/métodos , Administración Oral , Anciano , Anciano de 80 o más Años , Enfermedad Crónica , Dermatitis Exfoliativa/patología , Fármacos Dermatológicos/administración & dosificación , Femenino , Humanos , Masculino , Pronóstico , Recurrencia , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
Mycosis fungoides is the most common form of cutaneous T cell lymphoma. Although normally presenting to physicians at an early stage and with an indolent course, mycosis fungoides can have a varied presentation. The National Comprehensive Cancer Network (NCCN) has created guidelines for the treatment and staging of mycosis fungoides. Although comprehensive, in practice these guidelines do not provide specific treatment regimens for lesions located in difficult locations and those recalcitrant to the recommended therapy. Because of this, suggestions based on the practices and decisions made at the multidisciplinary cutaneous lymphoma clinic at the Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, USA, are presented here. Lesions located in areas such as the face and intertriginous zones are often challenging to treat because first-line therapies are often inappropriate, with the locations increasing the possibility of side effects. Additionally, lesions located in the bathing suit distribution are often nonresponsive to first-line therapies for reasons still undetermined. Finally, although well-described, erythroderma secondary to mycosis fungoides is challenging to treat, with controversy surrounding various methods of control. This article both highlights difficult clinical scenarios and reviews the recommended treatment as provided by the NCCN guidelines and provides alternative therapy for lesions that are either difficult to treat because of the location or are recalcitrant to the recommended therapy. With suggestions for the apparent gaps in guidelines, providers can better treat patients who present with more complicated conditions.
Asunto(s)
Dermatitis Exfoliativa/terapia , Micosis Fungoide/terapia , Neoplasias Cutáneas/terapia , Adulto , Antineoplásicos/administración & dosificación , Biopsia , Nalgas , Terapia Combinada/métodos , Dermatitis Exfoliativa/etiología , Fármacos Dermatológicos/administración & dosificación , Dermatología/normas , Fraccionamiento de la Dosis de Radiación , Cara , Femenino , Humanos , Masculino , Oncología Médica/normas , Persona de Mediana Edad , Micosis Fungoide/complicaciones , Micosis Fungoide/patología , Guías de Práctica Clínica como Asunto , Piel/efectos de los fármacos , Piel/patología , Piel/efectos de la radiación , Neoplasias Cutáneas/complicaciones , Neoplasias Cutáneas/patología , Resultado del Tratamiento , Terapia Ultravioleta/métodosAsunto(s)
Insuficiencia Suprarrenal/etiología , Anticuerpos Monoclonales/uso terapéutico , Dermatitis Exfoliativa/terapia , Glucocorticoides/efectos adversos , Psoriasis/terapia , Administración Cutánea , Insuficiencia Suprarrenal/diagnóstico , Anticuerpos Monoclonales Humanizados , Biopsia , Dermatitis Exfoliativa/diagnóstico , Dermatitis Exfoliativa/patología , Progresión de la Enfermedad , Femenino , Humanos , Persona de Mediana Edad , Psoriasis/diagnóstico , Psoriasis/patología , Diálisis Renal , Índice de Severidad de la Enfermedad , Piel/efectos de los fármacos , Piel/patología , Factores de Tiempo , Resultado del TratamientoAsunto(s)
Antibacterianos/efectos adversos , Síndrome de Hipersensibilidad a Medicamentos/etiología , Síndrome de Hipersensibilidad a Medicamentos/prevención & control , Levofloxacino/efectos adversos , Enfermedades Raras/etiología , Enfermedades Raras/prevención & control , Anciano , Antibacterianos/administración & dosificación , Artritis Reumatoide/complicaciones , Dermatitis Exfoliativa/terapia , Síndrome de Hipersensibilidad a Medicamentos/sangre , Síndrome de Hipersensibilidad a Medicamentos/diagnóstico por imagen , Femenino , Estudios de Seguimiento , Herpesvirus Humano 6 , Humanos , Levofloxacino/administración & dosificación , Linfadenopatía/terapia , Pruebas del Parche , Enfermedades Raras/sangre , Enfermedades Raras/diagnóstico por imagen , Esclerodermia Sistémica/complicaciones , Síndrome de Sjögren/complicaciones , Tomógrafos Computarizados por Rayos X , Resultado del TratamientoRESUMEN
The aim of this study was to describe the epidemiological, clinical, and therapeutic profile as well as the outcomes of children with erythroderma (also known as exfoliative dermatitis) in hospital dermatology departments in Lomé, Togo. This retrospective descriptive study examined the records of patients aged 0 to 15 years who were treated for erythroderma in dermatology departments in Lomé from January 1997 to December 2016. The study included 28 patients, with a mean age of 6.3 ± 5 years. The mean duration of progression of erythroderma before the consultation was 39.2 days. Pruritus was present in 60 % of the children, fever in 13.3 %, and impairment of general status in 3.3 %. Among the children aged 3 months and older, 84.2 % had dry squamous erythrodermic dermatosis, and among those younger than 3 months, 15.8 %. Among those with erythrodermic dermatosis, atopic dermatitis (70.6 %) was the most frequent dermatosis. No cause was found in 32.1 % cases. Course and outcome were favorable in 53.3 % of cases; one child died, and the rate of loss to follow-up was 43.3 %. Erythroderma is a rare disease in children in hospital dermatology departments in Lomé. Erythrodermic dermatosis, particularly atopic eczema, remains the most frequent cause.
Asunto(s)
Dermatitis Exfoliativa , Adolescente , Niño , Preescolar , Dermatitis Exfoliativa/diagnóstico , Dermatitis Exfoliativa/epidemiología , Dermatitis Exfoliativa/etiología , Dermatitis Exfoliativa/terapia , Dermatología , Femenino , Departamentos de Hospitales , Humanos , Lactante , Masculino , Estudios Retrospectivos , Togo/epidemiologíaRESUMEN
Erythroderma is an inflammatory skin syndrome that involves desquamation and erythema of more than 90% of the body surface area. It represents a final clinical endpoint for many adult dermatological conditions. The most frequent cause of erythroderma is psoriasis followed by eczematous conditions, drug-induced reactions, pityriasis rubra pilaris and cutaneous T-cell lymphomas. Diagnostic approach must include a thorough history and clinical examination. If the etiology of erythroderma is uncertain multiple skin biopsies may enhance diagnostic accuracy. The initial management of erythroderma must include a nutrition expert evaluation, fluid imbalance assessment, maintaining skin barrier function, sedative antihistamines and exclusion of secondary bacterial infection. We present a practical review of the etiology, diagnosis, and treatment of this entity.
Asunto(s)
Dermatitis Exfoliativa/diagnóstico , Dermatitis Exfoliativa/terapia , Adulto , Árboles de Decisión , HumanosAsunto(s)
Dermatitis Exfoliativa/terapia , Síndrome de Sézary/complicaciones , Neoplasias Cutáneas/complicaciones , Infecciones Estafilocócicas/tratamiento farmacológico , Antibacterianos/uso terapéutico , Antiinfecciosos Locales/uso terapéutico , Antiinflamatorios/uso terapéutico , Dermatitis Exfoliativa/etiología , Femenino , Humanos , Hidroterapia , Staphylococcus aureus Resistente a Meticilina , Persona de Mediana Edad , Infecciones Estafilocócicas/complicacionesAsunto(s)
Dermatitis Exfoliativa/diagnóstico , Dermatitis Exfoliativa/epidemiología , Centros de Atención Terciaria/tendencias , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Dermatitis Exfoliativa/terapia , Fármacos Dermatológicos/administración & dosificación , Femenino , Humanos , India/epidemiología , Masculino , Persona de Mediana Edad , Fototerapia/tendencias , Estudios Retrospectivos , Adulto JovenRESUMEN
Erythroderma can be life-threatening, primarily because of its metabolic burden and complications. It is mandatory to establish its etiopathology in order to facilitate precise and definitive management. This disorder may be the morphologic presentation of a variety of cutaneous and systemic diseases. Detailed history and thorough work-up is therefore essential. Management of erythroderma involves multi-disciplines with progress monitoring especially on signs and symptoms suggestive of acute skin failure induced complications. Early diagnosis and referral of erythroderma to centres with dermatological services is crucial and will directly affect the outcome of the patients.
Asunto(s)
Dermatitis Exfoliativa/diagnóstico , Urgencias Médicas , Adulto , Anciano , Dermatitis Exfoliativa/inducido químicamente , Dermatitis Exfoliativa/terapia , Servicio de Urgencia en Hospital , Humanos , Masculino , Cumplimiento de la Medicación , Psoriasis/diagnóstico , Psoriasis/etiología , Psoriasis/terapiaAsunto(s)
Dermatitis Exfoliativa/diagnóstico , Miasis/diagnóstico , Enfermedades Desatendidas/diagnóstico , Pénfigo/diagnóstico , Anciano , Dermatitis Exfoliativa/complicaciones , Dermatitis Exfoliativa/terapia , Humanos , Masculino , Miasis/complicaciones , Miasis/terapia , Enfermedades Desatendidas/complicaciones , Enfermedades Desatendidas/terapia , Pénfigo/complicaciones , Pénfigo/terapiaRESUMEN
Erythroderma consists on erythema and scaling that covers more than 90% of the cutaneous surface. It has multiple causes and for the most common we can use the acronym PALM (psoriasis, atopic dermatitis, lymphoproliferative disease and medication). It is important to diagnose the cause in order to get a prognosis and a targeted treatment. In 30% of the cases the cause is not evident and the patient requires periodic assessment to rule out evolution to a lymphoproliferative disease. In many cases, erythroderma is a chronic disease but it can also be a life-threatening dermatologic urgency that requires hospitalization.
La eritrodermia se caracteriza por eritema y escama en más del 90% de la superficie cutánea. Tiene muchas causas y es un reto para el dermatólogo identificarlas. Las más comunes se engloban en el acrónimo derivado de sus siglas en inglés PALM (psoriasis, dermatitis atópica, proceso linfoproliferativo y medicamentos). La importancia del diagnóstico certero es el tratamiento dirigido y el pronóstico. En los casos idiopáticos que llegan a ser de hasta el 30%, el paciente requiere de valoraciones periódicas por probable evolución a un proceso linfoproliferativo. Aunque en muchas ocasiones la eritrodermia es un cuadro crónico, también puede presentarse como una urgencia dermatológica que pone en riesgo la vida del paciente y requiere hospitalización.